Evidence map›Paper›PMID 39766783›Full record

ArticleGenes2024

Metachromatic Leukodystrophy in Morocco: Identification of Causative Variants by Next-Generation Sequencing (NGS).

Miloud Hammoud, María Domínguez-Ruiz, Imane Assiri, Daniel Rodrigues, Nisrine Aboussair, Val F Lanza, Jesús Villarrubia, Cristóbal Colón, Naima Fdil, Francisco J Del Castillo

Abstract read
In one paragraph

Article in Genes, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Miloud HammoudMetabolic Platform, Biochemistry Laboratory, Team for Childhood, Health and Development, Faculty of Medicine, Cadi Ayyad University, Marrakech B.P. 7010, Morocco.ORCID 0009-0004-9844-583X
María Domínguez-RuizServicio de Genética, Hospital Universitario Ramón y Cajal, IRYCIS, 28034 Madrid, Spain.ORCID 0000-0002-7583-0370
Imane AssiriMetabolic Platform, Biochemistry Laboratory, Team for Childhood, Health and Development, Faculty of Medicine, Cadi Ayyad University, Marrakech B.P. 7010, Morocco.
Daniel RodriguesCongenital Metabolic Diseases Unit, Department of Neonatology, University Clinical Hospital of Santiago de Compostela, Instituto de Investigación Sanitaria de Santiago (IDIS), European Reference Network for Hereditary Metabolic Disorders (MetabERN), 15706 Santiago de Compostela, Spain.ORCID 0000-0002-2934-1699
Nisrine AboussairGenetics Department, Clinical Research Center, Mohammed VI University Hospital, Faculty of Medicine and Pharmacy, Cadi Ayyad University, Marrakech-Principal B.P. 2360, Morocco.
Val F LanzaUCA de Genómica Traslacional y Bioinformática (UCA-GTB), Hospital Universitario Ramón y Cajal, IRYCIS, 28034 Madrid, Spain.
Jesús VillarrubiaServicio de Hematología, Hospital Universitario Ramón y Cajal, IRYCIS, 28034 Madrid, Spain.
Cristóbal ColónCongenital Metabolic Diseases Unit, Department of Neonatology, University Clinical Hospital of Santiago de Compostela, Instituto de Investigación Sanitaria de Santiago (IDIS), European Reference Network for Hereditary Metabolic Disorders (MetabERN), 15706 Santiago de Compostela, Spain.ORCID 0000-0002-9711-2812
Naima FdilMetabolic Platform, Biochemistry Laboratory, Team for Childhood, Health and Development, Faculty of Medicine, Cadi Ayyad University, Marrakech B.P. 7010, Morocco.
Francisco J Del CastilloServicio de Genética, Hospital Universitario Ramón y Cajal, IRYCIS, 28034 Madrid, Spain.ORCID 0000-0003-0467-4320

Funding

Sanofi (Spain) LYSOSPAIN
6 · The paper itself

Abstract

(1) Background: Most rare disease patients endure long delays in obtaining a correct diagnosis, the so-called "diagnostic odyssey", due to a combination of the rarity of their disorder and the lack of awareness of rare diseases among both primary care professionals and specialists. Next-generation sequencing (NGS) techniques that target genes underlying diverse phenotypic traits or groups of diseases are helping reduce these delays; (2) Methods: We used a combination of biochemical (thin-layer chromatography and high-performance liquid chromatography-tandem mass spectrometry), NGS (resequencing gene panels) and splicing assays to achieve a complete diagnosis of three patients with suspected metachromatic leukodystrophy, a neurologic lysosomal disorder; (3) Results: Affected individuals in each family were homozygotes for harmful variants in the

Indexed as

Cerebroside-SulfataseHigh-Throughput Nucleotide SequencingLeukodystrophy, MetachromaticAdultChildChild, PreschoolFemaleHumansMaleMoroccoMutationPedigreeTransferases (Other Substituted Phosphate Groups)Cerebroside-SulfataseTransferases (Other Substituted Phosphate Groups)functional assayslysosomal diseasesmetachromatic leukodystrophyNGSphenotypic variationrare diseases

Identifiers

PMID39766783
PMCPMC11675868

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.